Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 180

Results For "C"

9977 News Found

SMS Pharmaceuticals reports consolidated Q1 FY26 at Rs. 20.49 Cr
News | August 11, 2025

SMS Pharmaceuticals reports consolidated Q1 FY26 at Rs. 20.49 Cr

SMS Pharmaceuticals has reported total income of Rs. 196.64 crores during the period ended June 30, 2025


LAXAI Life Sciences appoints Sripathy Venkatraman as CEO
People | August 11, 2025

LAXAI Life Sciences appoints Sripathy Venkatraman as CEO

Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives


Emcure Pharmaceuticals reports Q1 FY26 consolidated PAT higher at Rs. 206.95 Cr
News | August 11, 2025

Emcure Pharmaceuticals reports Q1 FY26 consolidated PAT higher at Rs. 206.95 Cr

Emcure Pharmaceuticals has reported total income of Rs. 2,104.23 crores during the period ended June 30, 2025


Wockhardt reports Q1 FY26 loss at Rs. 108 Cr
News | August 10, 2025

Wockhardt reports Q1 FY26 loss at Rs. 108 Cr

Consolidated revenue from operations in the quarter was marginally down at Rs 738 crore a


Divis Laboratories posts consolidated Q1 FY26 PAT of Rs. 545 Cr
News | August 10, 2025

Divis Laboratories posts consolidated Q1 FY26 PAT of Rs. 545 Cr

Divi's Laboratories has reported total income of Rs. 2,529 crores during the period ended June 30, 2025


Morepen Laboratories consolidated Q1 FY26 PAT lower at Rs. 11.40 Cr
News | August 10, 2025

Morepen Laboratories consolidated Q1 FY26 PAT lower at Rs. 11.40 Cr

Morepen Laboratories has reported total income of Rs. 429.64 crores during the period ended June 30, 2025


KIMS Q1 FY26 consolidated profit slips to Rs. 78.6 Cr
News | August 10, 2025

KIMS Q1 FY26 consolidated profit slips to Rs. 78.6 Cr

KIMS has reported total income of Rs. 878.7 crores during the period ended June 30, 2025


Aurobindo Pharma Q1 FY26 PAT slips 10% YoY to Rs. 824 Cr
News | August 10, 2025

Aurobindo Pharma Q1 FY26 PAT slips 10% YoY to Rs. 824 Cr

Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore


Zydus receives final approval from USFDA for Prucalopride Tablets
Drug Approval | August 09, 2025

Zydus receives final approval from USFDA for Prucalopride Tablets

Prucalopride is prescribed for chronic idiopathic constipation